STEVE ELMS
CIK 1250195 · last filed 2026-03-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$19.17M
Companies
9
Total Filings
59
Lifetime Open-Market Net
$6.06M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ADMA | Director | 2,136,750 | $8.79 | $18.78M | -$17.76M | 19 | 2026-03-09 |
| MRKR | Director | 328,338 | $1.18 | $387.4K | $2.04M | 8 | 2025-11-19 |
| Elevation Oncology, Inc. (ELEV) Delisted | Director | — | $0.36 | — | $0 | 3 | 2025-07-24 |
| Zosano Pharma Corp (ZSAN) Delisted | Director | 78,307 | $0.56 | $43.7K | $0 | 5 | 2021-06-14 |
| Loxo Oncology, Inc. (LOXO) Delisted | Director | 5,570,102 | — | — | $18.42M | 8 | 2019-02-15 |
| PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Director | 201,000 | — | — | $0 | 4 | 2016-05-31 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | 35,155 | $221.38 | $7.78M | $0 | 1 | 2015-04-22 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Director | 1,650,156 | $0.54 | $890.4K | $3.39M | 3 | 2014-09-04 |
| MAPP | Director | 0 | $27.00 | $0 | -$33.8K | 5 | 2010-05-24 |
Recent Filings · Page 2 of 6
59 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-12-02 | ADMA | Exer (M) | +9,000 | $97.2K | EDGAR |
| 2024-06-17 | Elevation Oncology, Inc. (ELEV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-03-19 | ADMA | Sell (S) | −461,716 | -$2.80M | EDGAR |
| 2024-03-15 | ADMA | Sell (S) | −1,038,284 | -$6.34M | EDGAR |
| 2024-02-28 | ADMA | Grant (A) | +24,040 | $0 | EDGAR |
| 2023-06-08 | MRKR | Grant (A) | — | $0 | EDGAR |
| 2023-03-08 | ADMA | Grant (A) | +25,815 | $0 | EDGAR |
| 2022-05-26 | MRKR | Grant (A) | — | $0 | EDGAR |
| 2022-03-09 | ADMA | Grant (A) | +26,586 | $0 | EDGAR |
| 2021-06-14 | Zosano Pharma Corp (ZSAN) Delisted | Grant (A) | +15,000 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.